Notably,they havebeen identified as protein tyrosine phosphatase 1B (PTP1B) inhibitors(Figure c), a promisingclass of compounds for Type II diabetes and cancer treatment.−,  Despite the clinical advancement of PTP1B inhibitors such as trodusquemine and ertiprotafib, their development stalled due to limited efficacy (Figure c). The gene discussed is PTPN1; the disease is type 2 diabetes mellitus.